Benefits & Risks

Zephyr Valve Treatment is Clinically Proven Safe and Effective Across Multiple Endpoints Out to At Least One Year

Zephyr Treatment Leads to Improved Health Status

Results from multiple randomized clinical trials of the Zephyr Valve have demonstrated clinically meaningful benefits in lung function, exercise capacity and quality of life (QoL).

 

The Zephyr Valve is clinically proven safe and effective in patients with either heterogeneous or homogeneous emphysema.

 

Randomized Controlled TrialsSample size & follow-up periodDifference EBV vs Control Groups (ITT)
LUNG FUNCTION
(FEV1%)
EXERCISE CAPACITY
(6MWD)
QUALITY OF LIFE
(SGRQ)
LIBERATE1
2:1 Randomization
Heterogeneous only
n=190
12 months
18.0%39 m-7.1 pts
TRANSFORM9
2:1 Randomization
Heterogeneous only
n=97
6 months
29.3%79 m-6.5 pts
IMPACT10
1:1 Randomization
Homogeneous only
n=93
6 months
16.3%28 m-7.5 pts
STELVIO11
1:1 Randomization
Heterogeneous & Homogeneous
n=68
6 months
17.8%74 m-14.7 pts*

*Completed Cases
Learn More About Patient Selection

Hear From an Expert

“The hope was we could place valves in the most affected regions of the lungs to allow the air to come out of those lobes and allow the better quality of the lung to expand in the chest and function better.”

Risks

Complications of the Zephyr Endobronchial Valve Treatment include but are not limited to pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.